Why the study?
Patients with systemic lupus erythematosus develop accelerated atherosclerosis and increased cardiovascular disease that traditional risk factors alone cannot explain.
Do HDL-targeted therapies reduce accelerated atherosclerosis and cardiovascular disease in patients with systemic lupus erythematosus?
Do HDL-targeted therapies reduce accelerated atherosclerosis and cardiovascular disease in patients with systemic lupus erythematosus?
Dysfunctional HDL may serve as a biomarker for accelerated atherosclerosis in SLE patients, highlighting HDL-targeted therapies as a potential intervention.
Answers are grounded in this paper and cite their sources.
Dysfunctional HDL may mark higher CV risk in SLE; leaves open whether targeted therapies can mitigate atherosclerosis.
Systemic lupus erythematosus (SLE) patients exhibit accelerated development of atherosclerosis and increased incidents of cardiovascular disease (CVD) that cannot be explained by traditional risk factors alone. Accumulating evidence suggests that reduced levels of high-density lipoproteins (HDLs), along with altered HDL composition and function, may contribute to the accelerated atherosclerosis in SLE patients. Normally, HDLs play various atheroprotective roles through facilitating cholesterol efflux, inhibiting vascular inflammation, and scavenging oxidative species. However, systemic inflammation, oxidative stress, and autoimmunity in SLE patients induce changes in HDL size distribution and proteomic and lipidomic signatures. These compositional changes in HDLs result in the formation of proinflammatory, dysfunctional HDL. These lupus-altered HDLs have impaired antiatherogenic function with reduced cholesterol efflux capacities, impaired antioxidation abilities, and diminished antiinflammatory properties. In fact, dysfunctional HDL may promote atherogenesis by inducing inflammation. Thus, dysfunctional HDLs could be an important biomarker of accelerated atherosclerosis in lupus. Additionally, HDL-targeted therapies, especially infusion of reconstituted HDLs, may serve as a potential therapeutic intervention for SLE patients with CVD.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: